Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with older ADs (moderate certainty).
Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with sertraline (moderate certainty).
Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with tianeptine (moderate certainty).
Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with trazodone (moderate certainty).
Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with venlafaxine (low certainty).
Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with amisulpride (moderate certainty).
Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with bupropion (moderate certainty).
Paroxetine probably leads to higher failure to respond at endpoint (6‐12 weeks) compared with citalopram (moderate certainty).
Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with duloxetine (moderate certainty).
Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with escitalopram (moderate certainty).
Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with fluoxetine (moderate certainty).
Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with fluvoxamine (moderate certainty).
Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with hypericum (moderate certainty).
Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with milnacipran (moderate certainty).
Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with agomelatine (moderate certainty).
Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with mirtazapine (moderate certainty).
Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with nefazodone (moderate certainty).
Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with reboxetine (moderate certainty).